Biomea Fusion Inc (BMEA) News

Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Biomea Fusion Announces Leadership Transition

Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann...

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in...